Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-05-03
2011-05-03
Shameem, Golam M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S106000, C544S111000, C544S146000, C544S359000, C546S268100, C549S029000, C549S070000, C549S072000, C514S336000, C514S438000, C514S444000
Reexamination Certificate
active
07935696
ABSTRACT:
A compound of Formula Iand enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula I, and methods of treating conditions associated with the activity of p38 kinase.
REFERENCES:
patent: 4200750 (1980-04-01), Warner, Jr. et al.
patent: 5658903 (1997-08-01), Adams et al.
patent: 5932576 (1999-08-01), Anantanarayan et al.
patent: 5945418 (1999-08-01), Bemis et al.
patent: 5977103 (1999-11-01), Adams et al.
patent: 6087496 (2000-07-01), Anantanarayan et al.
patent: 6130235 (2000-10-01), Mavunkel et al.
patent: 6147080 (2000-11-01), Bemis et al.
patent: 6251914 (2001-06-01), Adams et al.
patent: 6277989 (2001-08-01), Chakravarty et al.
patent: 7151113 (2006-12-01), Dyckman et al.
patent: 7253170 (2007-08-01), Dyckman et al.
patent: 7390810 (2008-06-01), Dyckman et al.
patent: 7396935 (2008-07-01), Dyckman et al.
patent: 7414056 (2008-08-01), Dyckman et al.
patent: 7419978 (2008-09-01), Das et al.
patent: 7592338 (2009-09-01), Dyckman et al.
patent: 7605273 (2009-10-01), Dyckman et al.
patent: 7642257 (2010-01-01), Das et al.
patent: 7652146 (2010-01-01), Chen et al.
patent: WO 00/07980 (2000-02-01), None
patent: WO 00/12074 (2000-03-01), None
patent: WO 00/12497 (2000-03-01), None
patent: WO 00/55120 (2000-09-01), None
patent: WO 00/56738 (2000-09-01), None
patent: WO 01/27089 (2001-04-01), None
patent: WO 01/34605 (2001-05-01), None
patent: WO 02/14308 (2002-02-01), None
patent: WO 03/032970 (2003-04-01), None
patent: WO 03/032986 (2003-04-01), None
patent: WO 2004/071440 (2004-08-01), None
patent: WO 2004/099156 (2004-11-01), None
patent: WO 2005/061465 (2005-07-01), None
patent: WO 2005/115374 (2005-12-01), None
patent: WO 2006/067445 (2006-06-01), None
Das et al (2005): STN International HCAPLUS database, (Columbus, Ohio), Accession No. 2005:409524.
Brown et al (2005): STN International HCAPLUS database, (Columbus, Ohio), Accession No. 2005:588911.
Bundgaard, H., Design of Prodrugs, 1985 Elsevier.
Bundgaard, H., “Means to Enhance Penetration, Prodrugs as a means to improve the delivery of peptide drugs”, Advanced Drug Delivery Reviews, vol. 8, pp. 1-38 (1992).
Carman, R.M. et al., “Conversion of Sucrose into a Carboxylic Acid”, Journal of Chemical Education, vol. 46(12), pp. 847-848 (1969).
Corwin, A. et al., “The Condensation of Pyrroles with Bromine. A Self-Oxidation and a New Type of Displacement Reaction”, Journal of American Chemical Society, vol. 66, pp. 1137 (1944).
Greene, T. et al., Protective Groups in Organic Synthesis, Wiley & Sons (1991).
Henry, J. et al., “p38 mitogen-activated protein kinase as a target for drug discovery”, Drugs of the Future, vol. 24(12), pp. 1345-1354 (1999).
Katritzky, A. et al., Comprehensive Heterocyclic Chemistry II, The Structure, Reactions, Synthesis, and Users of Heterocyclic Compounds, vol. 5, pp. 91-133 (1996).
Krogsgaard-Larsen, P. et al., “Design and Application of Prodrugs”, A Textbook of Drug Design and Development, pp. 113-191 (1991).
Larock, R., Comprehensive Organic Transformations. A Guide to Functional Group Preparation, VCH Publishers Inc., pp. 385-439 (1989).
Lisowski, V. et al., “Design, Synthesis, and Evaluation of Novel Thienopyrrolizinones as Antitubulin Agents”, J. Med. Chem., vol. 47, pp. 1448-1464 (2004).
Moreland, L. et al., “Etanercept Therapy in Rheumatoid Arthritis”, Ann. Inter Med., vol. 130, pp. 478-486 (1999).
Notari, R., “Theory and Practice of Prodrug Kinetics”, Methods in Enzymology, vol. 112, pp. 309-323 (1985).
Raingeaud, J. et al., “MKK3- and MKK6-Regulated Gene Expression is Mediated by the p38 Mitogen-Activated Protein Kinase Signal Transduction Pathway”, Molecular and Cellular Biology, vol. 16(3), pp. 1247-1255 (1996).
Rankin, E. et al., “The Therapeutic Effects of an Engineered Human Anti-Tumour Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis”, British Journal of Rheumatology, vol. 34, pp. 334-342 (1995).
Salituro, F. et al., “Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Diseases”, Current Medicinal Chemistry, vol. 6, pp. 807-823 (1999).
Das Jagabandhu
Dhar T. G. Murali
Dyckman Alaric J.
Hynes John
Leftheris Katerina
Bristol--Myers Squibb Company
Duncan Laurelee A.
Shameem Golam M
LandOfFree
Heterocyclic amide compounds useful as kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic amide compounds useful as kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic amide compounds useful as kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2681823